Radiation safety considerations for the bone seeking radiopharmaceuticals89SrCl2, 186Re-HEDP and153Sm-EDTMP;Betrachtungen zur Strahlensicherheit der osteotropen Nuklide 89SrCl2,186Re-HEDP und153Sm-EDTMP

NuklearMedizin

Volumn 48, Issue 1, 2009, Pages 37-43

  Lam, M G E H ^a,b   Hoekstra, A ^a   De Klerk, J M H ^a,c   Van Rijk, P P ^a   Zonnenberg, B A ^a,b  

^a Department of Nuclear Medicine ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Bone metastases; Radiation safety; Rhenium; Samarium; Strontium

Indexed keywords

ETIDRONIC ACID RE 186; LEXIDRONAM SAMARIUM SM 153; STRONTIUM 89;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAMMA RADIATION; HUMAN; MALE; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION EXPOSURE; RADIATION SAFETY;

ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOISOTOPES; RHENIUM; SAFETY; SAMARIUM; STRONTIUM; STRONTIUM RADIOISOTOPES;

EID: 62549159985     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0182     Document Type: Article

References (11)

1. De Klerk JM, van Dijk A, van het Schip AD et al. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646-651.
2. 186Re- etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002; 43: 1150-1156.
3. ICRP. Conversion Coefficients for use in Radiological Protection against External Radiation. Annals of the ICRP 74 26/3.
4. Laing AH, Ackery DM, Bayly RJ et al. Stron- tium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816-822.
5. 153Sm-ethylenediaminetetra- methylenephosphonate in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33: 1583-1591.
6. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420-424.
7. Sartor O, Reid RH, Hoskin PJ et al. Samari- um-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 940-945.
8. 186Re-1,1-hydroxyethylidene di- phosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41: 647-654.
9. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-53 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-1581.
10. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nucl Med 1991; 32: 174-185.
11. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med 1999; 40: 1024-1028.